13-3406(A)(7) The indictment alleges that between January 1, 2026, and April 28, 2026, Holladay obtained money, business, or customers through fraudulent pretenses, including failing to disclose that she was not a licensed medical provider, that SlimSlays had no licensed medical provider authorized to prescribe prescription-only drugs, and that the business had no state-licensed medical director providing legally-mandated clinical oversight
Co-agonist strategy Glucose-dependent insulinotropic polypeptide (GIP) and glucagon receptor (GCGR) are currently the primary targets alongside GLP-1R for combined stimulation
In May 2024 Novo Nordisk announced that an upcoming clinical trial would investigate GLP-1 drugs as a treatment for liver diseaseand explore their effects on alcohol consumption
That word carries weight
these patients had more recent interactions, and therefore, may be less healthy than the general population receiving GLP-1s